Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Monotherapy vs Combination with Mesalamine in UC
NCT06625450Phase 4Not yet recruiting
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of tofacitinib in ulcerative colitis (UC) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Time to relapse of colitis at 12 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06625450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625450.